Tricyclic Spiro EP4 Antagonists With Improved Pharmacokinetics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing compounds do not effectively target the EP4 receptor with strong antagonistic activity and desirable pharmacokinetics for the prevention and treatment of diseases caused by its activation.
Innovation Solution
Development of tricyclic spiro compounds represented by general formula (I) that act as potent EP4 receptor antagonists, offering improved pharmacokinetic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing compounds are used to target the EP4 receptor, then some level of receptor binding is achieved, but strong antagonistic activity and desirable pharmacokinetics are not simultaneously obtained
Solution Approach 1:
The patent modifies molecular parameters of the compound structure, specifically incorporating a tricyclic spiro core with specific substituent patterns (R1-R10 groups) to optimize both binding affinity and pharmacokinetic properties. The general formula (I) represents a systematic exploration of structural parameters to achieve the desired dual performance.
Solution Approach 2:
The invention creates a composite molecular structure combining a tricyclic spiro core framework with various functional substituent groups. This composite approach allows integration of multiple functional elements that work synergistically to provide both strong receptor antagonism and favorable pharmacokinetic characteristics.
2Reliability
If compounds are designed to bind strongly to the EP4 receptor, then antagonistic activity is improved, but pharmacokinetic properties may deteriorate
Solution Approach 1:
The patent applies local quality modification by introducing specific functional groups at particular positions on the tricyclic spiro core structure. Different substituent patterns (R1-R10) are placed at specific locations to locally optimize binding interactions while maintaining overall pharmacokinetic stability.
Solution Approach 2:
The invention incorporates dynamic elements through flexible linking groups and variable substituent configurations that allow the molecule to adapt its conformation for optimal receptor binding while maintaining stable pharmacokinetic properties through the rigid tricyclic spiro framework.
Data Source
AI summary
A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation is disclosed. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.